Gsk Share Discussion Threads

[toffeeman] 05/4/2022 14:06

Not quite sure where the shoulders are but sure looks like an inv H&S

[pcok] 05/4/2022 14:02

How about look at the SP

[jonjoneil] 04/4/2022 14:50

Oh dear. Sotrovimab found to be ineffective against dominant strain of Covid-19.



about time there was some good news

[mattboxy] 04/4/2022 07:12

This is him after his meds! He's a bit conspiracy theory on everything- you know the sort!

[charlie9038] 01/4/2022 17:55

You have Issues best take your meds

[tradermichael] 30/3/2022 12:23

CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV
Published: Mar 30, 2022

Phase 1 dose-escalation study started at clinical sites in the U.S.
Milestone demonstrates CureVac's and GSK's continued execution on comprehensive clinical program of second-generation vaccine candidates for infectious diseases
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / March 30, 2022 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that the first participant was dosed in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed in collaboration with GSK. The clinical trial is expected to provide valuable data to further evaluate the performance of CureVac's second-generation mRNA backbone, which has the potential to be applied broadly in future vaccines against COVID-19 variants and other pathogens.

A preclinical study of CV2CoV in cynomolgus macaques, published in Nature in November 2021, demonstrated rapid induction of higher antibody titers, better induction of immune memory and stronger protective efficacy of CV2CoV compared to CureVac's first-generation vaccine candidate, CVnCoV. The same study demonstrated comparable neutralizing antibody titers in animals fully vaccinated with either 12µg of CV2CoV or a 30µg standard dose of a licensed mRNA COVID-19 vaccine.

"Continued innovation and progress in the development of mRNA-based vaccines is a critical prerequisite to combat the evolving COVID-19 pandemic and to further extend the possibilities of mRNA technology to a broad range of indications," said Dr. Klaus Edvardsen, Chief Development Officer of CureVac. "Our second-generation mRNA backbone was engineered to enable faster and stronger immune responses than our first-generation vaccine. This Phase 1 trial of CV2CoV will provide clinical data to further establish this backbone as a basis to flexibly address not only different COVID-19 variants, but also a range of other diseases and potential combination vaccines."

The Phase 1 dose-escalation study is being conducted at clinical sites in the U.S. and is expected to enroll up to 210 healthy adults to evaluate the safety, reactogenicity and immunogenicity of CV2CoV in the dose range of 2 to 20µg. Data results from the Phase 1 study are expected in the second half of 2022. The program follows the recent start of the Phase 1 clinical study for the jointly developed seasonal influenza vaccine candidate, CVSQIV, also applying the optimized second-generation mRNA backbone.

The CureVac-GSK infectious disease collaboration was first announced in July 2020 and focuses on the development of new products based on CureVac's mRNA technology for different targets in the field of infectious diseases. In 2022, both companies have broadened their development strategy to test chemically modified mRNA technologies in addition to unmodified mRNA. Clinical programs with chemically modified mRNA for COVID-19 and influenza are expected to start later this year.

[jonjoneil] 30/3/2022 10:24

net
that's good - it wasn't lost on me.

[jonjoneil] 30/3/2022 10:15

Jretlaw
In very simple terms, it's the Market's perception of where the company is heading. It's about confidence in the management to make the right decisions to move the company forward in the right direction. The reason why any early gain in a day falls away before the close is that the confidence is missing. IMHO.

[netcurtains] 30/3/2022 08:44

Mary Poppins without the Magic?
That would be "the Sound of Music".

[jretlaw] 30/3/2022 08:41

What drives a companies share price !?

[jonjoneil] 29/3/2022 16:03

Yep - AZN powering ahead while GSK can't even find a gear. It's Pascal Soriot vs Dame Mary Poppins (without the magic). No contest

[gateside] 29/3/2022 15:45

Same old story...

AZN held onto most of its daily gains, while GSK falls back!

[netcurtains] 29/3/2022 15:19

Yes, I am.

[jonjoneil] 29/3/2022 15:12

reversed back through 1650p. Anyone the least surprised?

[gateside] 29/3/2022 09:52

Can't find monty's Goodbody target of 1950p

But let's hope GSK starts heading in that direction

[netcurtains] 29/3/2022 09:49

Gone through 1650p

[gateside] 29/3/2022 09:48

AZN through 10000p today :-)

How's GSK doing?

[tradermichael] 29/3/2022 09:33

Interesting - do you know what price they raised from?

[montyhedge] 29/3/2022 08:57

GSK raised to Buy at Goodbody target 1950p.

[geckotheglorious] 29/3/2022 08:53

US agency pauses distribution of GSK, Vir's COVID-19 therapy sotrovimab in certain states

On March 25, the U.S. government paused the distribution of GlaxoSmithKline (NYSE:GSK) and Vir Biotechnology's (NASDAQ:VIR) COVID-19 antibody therapy sotrovimab in certain states after the FDA amended its emergency use authorization noting the drug's weakness against Omicron subvariant.

The Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services paused distribution of sotrovimab to all states in Region 1 (Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont) and Region 2 (New Jersey, New York, Puerto Rico, and the Virgin Islands).

The agency said the CDC had identified that the BA.2 variant was circulating with a frequency exceeding 50% in HHS Region 1 and Region 2.

The companies had said that the FDA determined that, based on the available evidence, including new live virus data generated by Vir, it was unlikely that the sotrovimab 500 mg dose would be effective against the Omicron BA.2 variant.

ASPR added that other states, except those mentioned were not impacted by the decision.

ASPR noted that currently authorized alternative treatments are available for distribution: which includes Pfizer's (PFE) Paxlovid; Merck (MRK) and Ridgeback Biotherapeutics' COVID-19 pill molnupiravir; and Eli Lilly's (LLY) bebtelovimab.

ASPR said that based on similar in vitro assay data currently available, these products are likely to retain activity against the BA.2 variant.

[netcurtains] 25/3/2022 13:24

Cool so lets split the difference, most likely will be (1650 + 3000) / 2 = 2325

Still quite a good price.

Is this target with or without including dividends?

[jonjoneil] 25/3/2022 13:15

My aggressive target for 12 months is 1650.(New GSK + Haleon(adjusted)). If it gets back to 1700 I will be out. I am fed up with this long term laggard.

[netcurtains] 25/3/2022 12:56

So we all agree GSK going up big time.
Whats your target price?
I'm going for 3000 over 12 months.